Nulibry

Active Ingredient(s): Fosdenopterin
FDA Approved: * February 26, 2021
Pharm Company: * ORIGIN BIOSCIENCES INC
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Nulibry Overview

Fosdenopterin (or cyclic pyranopterin monophosphate, cPMP), sold under the brand name Nulibry, is a medication used to reduce the risk of death due to a rare genetic disease known as molybdenum cofactor deficiency type A (MoCD-A).[1] Contents 1 Adverse effects 2 Mechanism of action 3 History 4 References 5 External links Adverse effects The most common side effects include complications related to the intravenous line, fever, respiratory infections, vomiting, gastroente...

Read more Nulibry Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Fosdenopterin

Recent Nulibry Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Fosdenopterin
  • Injection: 9.5mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Fosdenopterin or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 20 April 2021.

We are committed to your privacy.

Copyright © 2005-2021 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA